Rezular – Oral Treatment for IBS

 
Key Data:
Drug (brand/generic)
Rezular (arverapamil)
Company/licensee
AGI Therapeutics
Therapy class
Not defined
Product description
Triple-action intestinal regulator for IBS-D
Current indication
Diarrhoea-predominant IBS
Market sector
GI
Development status
Phase III

Return to Project



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development